Literature DB >> 22116524

Tangle evolution linked to differential 3- and 4-repeat tau isoform deposition: a double immunofluorolabeling study using two monoclonal antibodies.

Toshiki Uchihara1, Makoto Hara, Ayako Nakamura, Katsuiku Hirokawa.   

Abstract

Double immunofluorolabeling for 3-repeat (3R) and 4-repeat (4R) tau was performed with two monoclonal antibodies, RD3 and RD4, after an additional pretreatment with potassium permanganate and oxalic acid to eliminate nonspecific 3R tau cytoplasmic staining. This method involves hyperdilution of one of the primary monoclonal antibodies (≥100-fold), making it undetectable by usual secondary antibodies. The hyperdiluted primary antibody can then only be detected after tyramide amplification. Subsequent application of the other monoclonal antibody at its usual concentration allows double immunofluorolabeling without cross-reaction. This novel method revealed that tau immunoreactivity (IR) in the hippocampal pyramidal neurons of Alzheimer's disease (AD) brains is heterogeneous in that pretangle neurons exhibit 4R-selective (3R-/4R+) IR, ghost tangles exhibit 3R-selective (3R+/4R-) IR, and neurofibrillary tangles exhibit both 3R and 4R (3R+/4R+) IR. Some nigral neurons exhibited RD3 IR in both AD and corticobasal degeneration/progressive supranuclear palsy (CBD/PSP) brains. However, in CBD/PSP cases, 3R IR was always superimposed on 4R IR, while 3R-selective neurons were present in AD cases. These differential isoform profiles may provide a pivotal molecular reference, closely related to the morphological evolution of tau-positive neurons, which may be variable according to disease (CBD/PSP vs. AD), lesion site (cerebral cortex and substantia nigra), or the stage of evolution (from pretangles to ghost tangles). These findings should provide a more comprehensive understanding of the histological differentiation of various tau deposits in human neurodegenerative disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22116524     DOI: 10.1007/s00418-011-0891-2

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  30 in total

1.  Differential incorporation of tau isoforms in Alzheimer's disease.

Authors:  Marisol Espinoza; Rohan de Silva; Dennis W Dickson; Peter Davies
Journal:  J Alzheimers Dis       Date:  2008-05       Impact factor: 4.472

2.  Immunohistochemical signal amplification by catalyzed reporter deposition and its application in double immunostaining.

Authors:  B Hunyady; K Krempels; G Harta; E Mezey
Journal:  J Histochem Cytochem       Date:  1996-12       Impact factor: 2.479

3.  Pale neurites, premature α-synuclein aggregates with centripetal extension from axon collaterals.

Authors:  Toshiro Kanazawa; Eijiro Adachi; Satoshi Orimo; Ayako Nakamura; Hidehiro Mizusawa; Toshiki Uchihara
Journal:  Brain Pathol       Date:  2011-08-16       Impact factor: 6.508

4.  Evolution from pretangle neurons to neurofibrillary tangles monitored by thiazin red combined with Gallyas method and double immunofluorescence.

Authors:  T Uchihara; A Nakamura; M Yamazaki; O Mori
Journal:  Acta Neuropathol       Date:  2001-06       Impact factor: 17.088

5.  Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies.

Authors:  Mari Yoshida
Journal:  Neuropathology       Date:  2006-10       Impact factor: 1.906

6.  Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease.

Authors:  K A Jellinger; J Attems
Journal:  Acta Neuropathol       Date:  2006-11-07       Impact factor: 17.088

7.  Hippocampal tau pathology is related to neuroanatomical connections: an ageing population-based study.

Authors:  G Lace; G M Savva; G Forster; R de Silva; C Brayne; F E Matthews; J J Barclay; L Dakin; P G Ince; S B Wharton
Journal:  Brain       Date:  2009-03-24       Impact factor: 13.501

8.  Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders.

Authors:  I Litvan; J J Hauw; J J Bartko; P L Lantos; S E Daniel; D S Horoupian; A McKee; D Dickson; C Bancher; M Tabaton; K Jellinger; D W Anderson
Journal:  J Neuropathol Exp Neurol       Date:  1996-01       Impact factor: 3.685

9.  Relationship between neuronal loss and tangle formation in neurons and oligodendroglia in progressive supranuclear palsy.

Authors:  Chenghua Jin; Sadao Katayama; Masanori Hiji; Chigusa Watanabe; Koichi Noda; Shigenobu Nakamura; Masayasu Matsumoto
Journal:  Neuropathology       Date:  2006-02       Impact factor: 1.906

10.  Abnormal Tau proteins in progressive supranuclear palsy. Similarities and differences with the neurofibrillary degeneration of the Alzheimer type.

Authors:  S Flament; A Delacourte; M Verny; J J Hauw; F Javoy-Agid
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

View more
  9 in total

Review 1.  The Histochemistry and Cell Biology compendium: a review of 2012.

Authors:  Douglas J Taatjes; Jürgen Roth
Journal:  Histochem Cell Biol       Date:  2013-05-12       Impact factor: 4.304

Review 2.  Biomarker modelling of early molecular changes in Alzheimer's disease.

Authors:  Ross W Paterson; Jamie Toombs; Catherine F Slattery; Jonathan M Schott; Henrik Zetterberg
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

3.  Brainstem tau pathology in Alzheimer's disease is characterized by increase of three repeat tau and independent of amyloid β.

Authors:  Miho Uematsu; Ayako Nakamura; Momoko Ebashi; Katsuiku Hirokawa; Ryosuke Takahashi; Toshiki Uchihara
Journal:  Acta Neuropathol Commun       Date:  2018-01-03       Impact factor: 7.801

Review 4.  Tau Filaments and the Development of Positron Emission Tomography Tracers.

Authors:  Michel Goedert; Yoshiki Yamaguchi; Sushil K Mishra; Makoto Higuchi; Naruhiko Sahara
Journal:  Front Neurol       Date:  2018-02-15       Impact factor: 4.003

5.  Detection of AD-specific four repeat tau with deamidated asparagine residue 279-specific fraction purified from 4R tau polyclonal antibody.

Authors:  Momoko Ebashi; Shuta Toru; Ayako Nakamura; Satoshi Kamei; Takanori Yokota; Katsuiku Hirokawa; Toshiki Uchihara
Journal:  Acta Neuropathol       Date:  2019-04-20       Impact factor: 17.088

6.  How to demix Alzheimer-type and PSP-type tau lesions out of their mixture -hybrid approach to dissect comorbidity.

Authors:  Momoko Ebashi; Yoshinori Ito; Miho Uematsu; Ayako Nakamura; Katsuiku Hirokawa; Satoshi Kamei; Toshiki Uchihara
Journal:  Acta Neuropathol Commun       Date:  2019-05-06       Impact factor: 7.801

Review 7.  Targeting Tau to Treat Clinical Features of Huntington's Disease.

Authors:  Maria Masnata; Shireen Salem; Aurelie de Rus Jacquet; Mehwish Anwer; Francesca Cicchetti
Journal:  Front Neurol       Date:  2020-11-19       Impact factor: 4.003

8.  Loss of Lysosomal Proteins Progranulin and Prosaposin Associated with Increased Neurofibrillary Tangle Development in Alzheimer Disease.

Authors:  Anarmaa Mendsaikhan; Ikuo Tooyama; Geidy E Serrano; Thomas G Beach; Douglas G Walker
Journal:  J Neuropathol Exp Neurol       Date:  2021-09-10       Impact factor: 3.148

Review 9.  Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research.

Authors:  Christina M Moloney; Val J Lowe; Melissa E Murray
Journal:  Alzheimers Dement       Date:  2021-04-02       Impact factor: 21.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.